L40.0
Conditions
Interventions
Group 1: Patients with initiation of therapy with MTX (methotrexate) - Evaluation of skin condition and 2 patient questionnaires in follow up.
Group 2: Patients with initiation of therapy with Fumade
Sponsors
Universitätsklinikum Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with plaque psoriasis who begin therapy with a conventional systemic drug (Apremilast, methotrexate or Fumaderm) at the Department of Dermatology at the University of Heidelberg. Patients must be at least 18 years old and give their written consent for study participation.
Exclusion criteria
Exclusion criteria: Patients who are younger than 18 years of age, or are not fluent of the German language. Furthermore, patients with psychiatric diagnoses are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of this study is to provide the quality of life, in the first 6 months of treatment, measured with the DLQI questionnaire and to compare these - in patients with conventional systemic therapies, with the approved drugs (Apremilast, methotrexate, Fumaderm). | — |
Secondary
| Measure | Time frame |
|---|---|
| The aim of this study is it furthermore in the first 6 months of Treatment, to measure and compare treatment satisfaction with the TSQM questionnaire - in patients with conventional systemic therapies (Apremilast, MTX, Fumaderm) | — |
Countries
Germany
Contacts
Public ContactKnut Schäkel
Universitätsklinikum Heidelberg
Outcome results
None listed